Brain and Central Nervous System Tumors Clinical Trial
Official title:
A Phase I Study of MK-0752 in Pediatric Patients With Recurrent or Refractory CNS Malignancies
RATIONALE: MK0752 may stop the growth of tumor cells by blocking some of the enzymes needed
for cell growth.
PURPOSE: This phase I trial is studying the side effects and best dose of MK0752 in treating
young patients with recurrent or refractory CNS cancer.
Status | Terminated |
Enrollment | 33 |
Est. completion date | February 2011 |
Est. primary completion date | February 2011 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 3 Years to 21 Years |
Eligibility |
DISEASE CHARACTERISTICS: - Histologically confirmed primary CNS tumor - Patients with intrinsic brain stem tumors do not require histologic verification, but must have radiographic evidence of progression - Recurrent disease or refractory to standard therapy - No histologically benign brain tumors (e.g., low-grade glioma) PATIENT CHARACTERISTICS: - Karnofsky performance status (PS) or Lansky PS 60-100% - Not pregnant or nursing - Negative pregnancy test - Fertile patients must use effective contraception - Absolute neutrophil count = 1,000/µL - Platelet count = 100,000/µL (unsupported) - Hemoglobin = 8 g/dL (RBC transfusions allowed) - Creatinine clearance OR glomerular filtration rate = 70 mL/min OR serum creatinine based on age as follows: - 0.8 mg/dL (= 5 years of age) - 1.0 mg/dL (> 5 to = 10 years of age) - 1.2 mg/dL (> 10 to = 15 years of age) - 1.5 mg/dL (> 15 years of age) - Bilirubin = 1.5 times upper limit of normal (ULN) for age - ALT = 2.5 times ULN for age - Albumin = 2.5 g/dL - Sodium, potassium, magnesium, and calcium normal - Patients with neurological deficits are eligible provided these deficits are stable for = 2 weeks prior to study registration - No clinically significant systemic illness (e.g., serious infection or significant cardiac, pulmonary, hepatic, or other organ dysfunction) that would compromise the patient's ability to tolerate study therapy or would likely interfere with the study procedures or results - No known hypersensitivity to MK0752 PRIOR CONCURRENT THERAPY: - Recovered from the acute toxic effects of all prior therapy - At least 3 weeks since prior myelosuppressive anticancer chemotherapy (6 weeks for nitrosoureas) - At least 7 days since prior investigational or biologic agents - At least 3 weeks since prior investigational or biologic agents that have a prolonged half-life or for which the patient has experienced = grade 2 myelosuppression in the treatment course preceding discontinuation of therapy - At least 3 half lives since prior monoclonal antibody therapy - At least 6 months since prior total body irradiation or craniospinal radiotherapy - At least 6 weeks since other prior substantial bone marrow irradiation - At least 2 weeks since prior local palliative radiotherapy (small volume) - At least 6 months since prior allogeneic bone marrow transplantation (BMT) - No evidence of active graft versus host disease - At least 3 months since prior autologous BMT or stem cell transplantation - At least 7 days since prior hematopoietic growth factors (filgrastim [G-CSF], sargramostim [GM-CSF], or erythropoietin) (14 days for long-acting formulations) - No prior MK0752 - No concurrent enzyme-inducing anticonvulsant drugs (EIACDs) - No other concurrent anticancer or investigational drug therapy - Concurrent dexamethasone allowed provided patient is on a stable or decreasing dose for = 2 weeks prior to study registration |
Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
United States | NCI - Pediatric Oncology Branch | Bethesda | Maryland |
United States | Dana-Farber/Harvard Cancer Center at Dana-Farber Cancer Institute | Boston | Massachusetts |
United States | Children's Memorial Hospital - Chicago | Chicago | Illinois |
United States | Cincinnati Children's Hospital Medical Center | Cincinnati | Ohio |
United States | Duke Comprehensive Cancer Center | Durham | North Carolina |
United States | Dan L. Duncan Cancer Center at Baylor College of Medicine | Houston | Texas |
United States | St. Jude Children's Research Hospital | Memphis | Tennessee |
United States | Children's Hospital of Philadelphia | Philadelphia | Pennsylvania |
United States | Children's Hospital of Pittsburgh | Pittsburgh | Pennsylvania |
United States | UCSF Helen Diller Family Comprehensive Cancer Center | San Francisco | California |
United States | Seattle Children's Hospital | Seattle | Washington |
United States | Children's National Medical Center | Washington | District of Columbia |
Lead Sponsor | Collaborator |
---|---|
Pediatric Brain Tumor Consortium | National Cancer Institute (NCI) |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Maximum tolerated dose | First 28 days of treatment | Yes | |
Primary | MK0752 systemic exposure | Serial blood samples for pharmacokinetic studies of MK-0752 will be collected with the first dose of course 1 at pre-specified times. | Day 1 of course 1 | No |
Secondary | Pharmacokinetics | Serial blood samples for pharmacokinetic studies of MK-0752 will be collected with the first dose of course 1 at pre-specified times. | Day 1 of course 1 | No |
Secondary | Toxicity | From day 1 of treatment until off study | Yes | |
Secondary | Objective response rate | Brain imaging to assess tumor response to the treatment is performed at baseline, at the end of courses 2, 4, 6 and at the end of therapy. | End of courses 2, 4, 6 and at the end of treatment | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT00788125 -
Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors
|
Phase 1/Phase 2 | |
Completed |
NCT00006080 -
Fenretinide in Treating Patients With Recurrent Malignant Glioma
|
Phase 2 | |
Recruiting |
NCT00887146 -
Radiation Therapy With Concomitant and Adjuvant Temozolomide Versus Radiation Therapy With Adjuvant PCV Chemotherapy in Patients With Anaplastic Glioma or Low Grade Glioma
|
Phase 3 | |
Suspended |
NCT00935090 -
3'-Deoxy-3'-[18F] Fluorothymidine PET Imaging in Patients With Cancer
|
N/A | |
Completed |
NCT00621686 -
Bevacizumab and Sorafenib in Treating Patients With Recurrent Glioblastoma Multiforme
|
Phase 2 | |
Terminated |
NCT00227032 -
Erlotinib in Treating Patients With Progressive Glioblastoma Multiforme
|
Phase 1 | |
Completed |
NCT00112502 -
Temozolomide Alone or in Combination With Thalidomide and/or Isotretinoin and/or Celecoxib in Treating Patients Who Have Undergone Radiation Therapy for Glioblastoma Multiforme
|
Phase 2 | |
Terminated |
NCT00243022 -
Dietary, Herbal and Alternative Medicine in Glioblastoma Multiforme
|
Phase 2 | |
Active, not recruiting |
NCT00278278 -
Combination Chemotherapy and Radiation Therapy With or Without Methotrexate in Treating Young Patients With Newly Diagnosed Gliomas
|
Phase 3 | |
Active, not recruiting |
NCT00087815 -
Hyperbaric Oxygen Therapy in Treating Patients With Radiation Necrosis of the Brain
|
N/A | |
Completed |
NCT00416819 -
Combination Chemotherapy and Rituximab in Treating Patients With Newly Diagnosed Primary CNS Lymphoma
|
N/A | |
Completed |
NCT00052286 -
Modafinil in Treating Fatigue and Behavioral Change in Patients With Primary Brain Cancer
|
N/A | |
Completed |
NCT00006093 -
EMD 121974 in Treating Patients With Progressive or Recurrent Glioma
|
Phase 1/Phase 2 | |
Recruiting |
NCT00004129 -
Phosphorus 32 in Treating Patients With Glioblastoma Multiforme
|
Phase 1 | |
Completed |
NCT00004212 -
DX-8951f in Treating Children With Advanced Solid Tumors or Lymphomas
|
Phase 1 | |
Completed |
NCT00003417 -
Computer Planned Radiation Therapy Plus Chemotherapy in Treating Patients With Glioblastoma Multiforme
|
Phase 1/Phase 2 | |
Completed |
NCT00003464 -
Temozolomide in Treating Adults With Newly Diagnosed Primary Malignant Glioblastoma Multiforme
|
Phase 2 | |
Completed |
NCT00003020 -
LMB-7 Immunotoxin in Treating Patients With Leptomeningeal Metastases
|
Phase 1 | |
Completed |
NCT00003173 -
High-Dose Thiotepa Plus Peripheral Stem Cell Transplantation in Treating Patients With Refractory Solid Tumors
|
Phase 2 | |
Completed |
NCT00008008 -
Thiotepa Followed by Peripheral Stem Cell or Bone Marrow Transplant in Treating Patients With Malignant Glioma
|
Phase 2 |